m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation

m6A Modification:
Crosstalk ID	M6ACROT03315				[1], [2]
Histone modification H3K9me1 JMJD1C hsa-miR-302a Indirect Inhibition m⁶A modification HSP90AA1 HSP90AA1 METTL3 Methylation : m⁶A sites
m6A Regulator	Methyltransferase-like 3 (METTL3)			WRITER	Regulator Info
m6A Target	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)				Targert Gene
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type	Histone modification (HistMod)
Epigenetic Regulator	Probable JmjC domain-containing histone demethylation protein 2C (JMJD1C)			ERASER	View Details
Regulated Target	Histone H3 lysine 9 monomethylation (H3K9me1)				View Details
Downstream Gene	hsa-miR-302a				View Details
Crosstalk Relationship	Histone modification → m6A			Inhibition
Crosstalk Mechanism	histone modification indirectly regulates m6A modification through downstream signaling pathways
Crosstalk Summary	JMJD1C increased MIR302A expression through promoting Histone H3 lysine 9 monomethylation (H3K9me1) demethylation at the miR-302a promoter region. miR-302a was identified to target METTL3, which could inhibit SOCS2 expression via m6A modification. m6A regulated cell proliferation by influencing apoptosis of U251 cells through regulating Heat shock protein HSP 90-alpha (HSP90/HSP90AA1) expression. m6A level was decreased in glioma tissue, which was caused by decreased METTL3 and increased FTO levels.
Responsed Disease	Brain cancer		ICD-11: 2A00		Disease Info
Pathway Response	Transcriptional misregulation in cancer				hsa05202
Cell Process	Cell migration and proliferation
In-vitro Model	LN-229	Glioblastoma	Homo sapiens		CVCL_0393
In-vitro Model	LN-18	Glioblastoma	Homo sapiens		CVCL_0392
In-vivo Model	Mice were subcutaneously injected with 2.5 × 10⁶ U251 cells stably infected with OE-NC, OE-JMJD1C, OE-NC and sh-NC, OE-JMJD1C and sh-NC or OE-JMJD1C and sh-SOCS2 (n = 10 in each group) in 0.1 ml PBS.

Full List of Potential Compound(s) Related to This m6A-centered Crosstalk

Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)		40 Compound(s) Regulating the Target	Click to Show/Hide the Full List
Compound Name	Cromoglicate		Approved	[3]
Synonyms	Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN) Click to Show/Hide
MOA	Inhibitor
External Link	CID: 2882 TTD: D06NSS DrugBank: DB01003
Compound Name	Amlexanox		Approved	[3]
Synonyms	ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid Click to Show/Hide
MOA	Inhibitor
External Link	CID: 2161 TTD: D0G5UB DrugBank: DB01025
Compound Name	NVP-AUY922		Phase 2	[4]
Synonyms	Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide Click to Show/Hide
MOA	Inhibitor
Activity	IC50 < 0.4 nM
External Link	CID: 135539077 TTD: D05BYA
Compound Name	BIIB-021		Phase 2	[5]
Synonyms	CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 1.7 nM
External Link	CID: 16736529 TTD: D05HWN DrugBank: DB12359
Compound Name	KW-2478		Phase 2	[6]
Synonyms	819812-04-9; KW-2478 free base; 2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide; UNII-QY50S617NM; KW 2478; KW2478; QY50S617NM; 2-ethyl-3,5-dihydroxy-n,n-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)benzeneacetamide; 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide Click to Show/Hide
MOA	Modulator
External Link	CID: 23116322 TTD: D08PYO
Compound Name	VER 50589		Phase 2	[4]
MOA	Inhibitor
External Link	CID: 135446210 TTD: D09XGB DrugBank: DB06964
Compound Name	Tanespimycin		Discontinued in Phase 3	[7]
Synonyms	CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 6505803 TTD: D0SC2J DrugBank: DB05134
Compound Name	Efungumab		Phase 2	[8]
Synonyms	Mycograb; Hsp90 mAb; Myc-123C28Y; Hsp90 mAb (cancer), NeuTec; Hsp90 mAb (Candida albicans infection/Cryptococcus neoformans meningitis), NeuTec Click to Show/Hide
External Link	TTD: D0Y9PZ
Compound Name	SNX-5422		Phase 1/2	[9]
Synonyms	908115-27-5; PF-04929113; SNX 5422; SNX5422; UNII-BF52J69Q8T; PF 04929113; PF-04929113 (SNX-5422); BF52J69Q8T; PF04929113; PF-4929113; cc-40; MLS006011083; SCHEMBL1220791; SCHEMBL1220790; CHEMBL1195136; SCHEMBL15604989; DTXSID50238270; C25H30F3N5O4; MolPort-023-293-502; BCPP000065; HMS3656B09; EX-A2343; BCP02427; s2656; ZINC95616595; ABP000737; ZINC100071931; ZINC252517142; AKOS027276395; SB16643; DB06070; API0008143; RL05706; SNX-5422 /; CS-0272; NCGC00346640-01; NCGC00386184-02; Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrah Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 38 nM
External Link	CID: 44195571 TTD: D07MPL DrugBank: DB06070
Compound Name	PU3		Phase 1	[4]
Synonyms	9-BUTYL-8-(3,4,5-TRIMETHOXYBENZYL)-9H-PURIN-6-AMINE; 352519-21-2; CHEMBL113690; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]purin-6-amine; 1uym; 1uy6; Purine-Based Inhibitor 1; AC1L9MK5; PU-3; SCHEMBL2604975; BDBM15374; CTK1B7081; DTXSID40332291; ZINC3832013; AKOS030562182; DB02754; KB-275186; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]- Click to Show/Hide
MOA	Inhibitor
External Link	CID: 448965 TTD: D02PGP DrugBank: DB02754
Compound Name	Debio 0932		Phase 1	[10]
MOA	Inhibitor
Activity	IC50 = 33 nM
External Link	CID: 44156921 TTD: D02TTL
Compound Name	Alvespimycin hydrochloride		Phase 1	[11]
Synonyms	Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG Click to Show/Hide
MOA	Inhibitor
External Link	CID: 9852573 TTD: D03LRU
Compound Name	AT13387		Phase 1	[12]
Synonyms	AT-13387 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 13.6 nM
External Link	CID: 11955716 TTD: D06YSP DrugBank: DB06306
Compound Name	BIIB 028		Phase 1	[13]
MOA	Inhibitor
External Link	TTD: D0H3VK
Compound Name	RTA-901		Phase 1	[14]
MOA	Modulator
External Link	TTD: D0ME2T
Compound Name	PU-AD		Phase 1	[14]
MOA	Inhibitor
External Link	TTD: D0V9MT
Compound Name	HBP-347		Discontinued in Phase 3	[15]
Synonyms	HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University Click to Show/Hide
MOA	Modulator
External Link	TTD: D03IKZ
Compound Name	Geldanamycin		Discontinued in Phase 2	[16]
Synonyms	GDM; GMY; Geldanamicin; Geldanomycin; Geldaramycin; Antibiotic U 29135; BODIPY-labeled Geldanamycin; Geldanamycin (9CI); Geldanamycin, Streptomyces hygroscopicus; U-29135; Antibiotic (U-29,135); [(8E,12E,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8E,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8Z,12Z,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10S,11S)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10R,11S,12Z,14E)-6-Hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; (6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate; [8S-(4E,6Z,8R,9R,10E,12R,13S,14R,16S)]-9-[(Aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione; 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9,13-dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, 9-carbamate (8CI); 2-Azabicyclo[16.3.1]docosane, geldanamycin deriv. Click to Show/Hide
MOA	Inhibitor
External Link	CID: 5288382 TTD: D03PKI DrugBank: DB02424
Compound Name	IPI-493		Discontinued in Phase 1	[17]
Synonyms	[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 9893658 TTD: D0BM6S DrugBank: DB13023
Compound Name	CCT-018159		Preclinical	[4]
Synonyms	CCT 018159; CCT018159; (6Z)-6-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1,2-dihydropyrazol-3-ylidene]-4-ethyl-3-hydroxycyclohexa-2,4-dien-1-one; 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 280 nM
External Link	CID: 984170 TTD: D00OCB DrugBank: DB07594
Compound Name	KOS-2484		Preclinical	[18]
Synonyms	KOS-2539; KOS-2540; HSP90 inhibitors (cancer), Kosan Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D0X5YU
Compound Name	EC-154		Terminated	[19]
Synonyms	Heat shock protein 90 inhibitors (cancer), Biogen Idec; Hsp 90inhibitors (cancer), Biogen Idec Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D0KC7K
Compound Name	8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-		Investigative	[20]
Synonyms	CHEMBL326564; PU6; 8-(1,3-benzodioxol-5-ylmethyl)-9-butyl-9H-purin-6-amine; 1uy9; Purine-Based Inhibitor 4; AC1L9MK7; BDBM15377; DB08436; 8-(1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(2H-1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(1,3-Benzodioxole-5-ylmethyl)-9-butyl-9H-purine-6-amine Click to Show/Hide
MOA	Inhibitor
External Link	CID: 448968 TTD: D00PMS DrugBank: DB08436
Compound Name	9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine		Investigative	[20]
Synonyms	CHEMBL109612; AC1NRCWL; 1uy8; Purine-Based Inhibitor 3; SCHEMBL1966787; BDBM15376; BWLWUGBHOXIUBP-UHFFFAOYSA-N; DB03809; 8-(3-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(3-methoxyphenyl)methyl]purin-6-amine; 9-Butyl-8-(3-methoxy-benzyl)-9H-purin-6-ylamine Click to Show/Hide
MOA	Inhibitor
External Link	CID: 5289228 TTD: D01GGU DrugBank: DB03809
Compound Name	KOSN1559		Investigative	[4]
MOA	Inhibitor
External Link	TTD: D02IIL
Compound Name	ZEARALANONE		Investigative	[21]
Synonyms	Zanone; 5975-78-0; (S)-Zearalanone; UNII-133DU2F2VS; CCRIS 9235; MLS000069626; P 1502; SMR000058193; CHEMBL491499; 133DU2F2VS; CHEBI:35051; beta-Resorcylic acid, 6-(10-hydroxy-6-oxoundecyl)-, mu-lactone; (S)-3,4,5,6,9,10,11,12-Octahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,5,6,9,10,11,12-octahydro-14,16-dihydroxy-3-methyl-, (S)-; 2,4-DIHYDROXY-6-[10-HYDROXY-6-OXO-UNDECYL]BENZOIC ACID MICRO-LACTONE Click to Show/Hide
MOA	Inhibitor
External Link	CID: 108003 TTD: D05GKC
Compound Name	17-desmethoxy-17-aminogeldanamycin		Investigative	[22]
Synonyms	UNII-SLQ1AJG3VB; SLQ1AJG3VB; 17-Aminogeldanamycin; 17-Amino-17-demethoxygeldanamycin; Geldanamycin, 17-amino-17-demethoxy-; 17-Amino Geldanamycin; SCHEMBL8250568; SCHEMBL16226317; XYFFWTYOFPSZRM-TWNAANEASA-N; DB13023; 1174669-94-3 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 91929099 TTD: D05RTH
Compound Name	9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine		Investigative	[20]
Synonyms	CHEMBL112834; 9-butyl-8-[(4-methoxyphenyl)methyl]purin-6-amine; 376629-53-7; PU4; AC1NRCWI; 1uy7; Purine-Based Inhibitor 2; SCHEMBL4320278; CTK1A9432; BDBM15375; DTXSID80415355; AKOS030562187; DB03899; 8-(4-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(4-methoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(4-methoxyphenyl)methyl]- Click to Show/Hide
MOA	Inhibitor
External Link	CID: 5289227 TTD: D05UTX DrugBank: DB03899
Compound Name	GNF-PF-67		Investigative	[21]
Synonyms	Toxoflavin; Toxoflavine; Xanthothricin; Xanthotricin; 84-82-2; Xanthothricin (VAN); UNII-5N5YI4IP1P; NSC 67078; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,6-Dimethylpyrimido(5,4-e)-as-triazine-5,7(1H,6H)-dione; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; BRN 0021014; 5N5YI4IP1P; MLS000087831; CHEBI:80729; NSC67078; 1,6-Dimethyl-5,7-dioxo-1,5,6,7-tetrahydropyrimido(5,4-E)-as-triazine-5,7(1H,6H)-dione; SMR000024051; Pyrimido(5,4-e)-as-triazine-5,7-(1H,6H)-dione, 1,6-dimethyl- Click to Show/Hide
MOA	Inhibitor
External Link	CID: 66541 TTD: D07WDQ
Compound Name	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine		Investigative	[20]
Synonyms	4-(2-methoxy-ethoxy)-6-methyl-pyrimidin-2-ylamine; 75435-54-0; 2wi1; AC1MWPG2; pyrimidin-2-amine, 11; CHEMBL538937; SCHEMBL10752783; BDBM33223; CCG-774; VCJHOFUOIQHNBC-UHFFFAOYSA-N; AKOS017529730; DB08786; 2-amino-4-(2-methoxyethoxy)-6-methylpyrimidine; 4-Methyl-6-(2-methoxyethoxy)pyrimidine-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidine-2-ylamine Click to Show/Hide
MOA	Inhibitor
External Link	CID: 3777900 TTD: D08CZD DrugBank: DB08786
Compound Name	6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE		Investigative	[20]
Synonyms	6-(3-bromonaphthalen-2-yl)-1,3,5-triazine-2,4-diamine; 2qf6; HSP90 Inhibitor, 1; SCHEMBL10822557; BDBM81729; DB07319 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 13373715 TTD: D0D3BP DrugBank: DB07319
Compound Name	PU24S		Investigative	[4]
MOA	Inhibitor
External Link	TTD: D0D5KQ
Compound Name	Macbecin		Investigative	[4]
MOA	Inhibitor
External Link	CID: 433447 TTD: D0H0KA
Compound Name	SNX-2112		Investigative	[22]
Synonyms	908112-43-6; SNX 2112; 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide; UNII-10C9P3FFOW; PF-04928473; 10C9P3FFOW; CHEMBL560895; SNX-2112 (PF-04928473); 945626-71-1; 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide; 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(cis-4-hydroxycyclohexyl)amino]benzamide Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 4 nM
External Link	CID: 24772860 TTD: D0K0TJ
Compound Name	2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol		Investigative	[20]
Synonyms	1-(2,4,6-trihydroxybenzoyl)pyrrole; 288839-58-7; 3eko; CHEMBL513225; DB08443; 2-(1-Pyrrolylcarbonyl)benzene-1,3,5-triol; 2-(pyrrole-1-carbonyl)benzene-1,3,5-triol Click to Show/Hide
MOA	Inhibitor
External Link	CID: 11160307 TTD: D0K4RN DrugBank: DB08443
Compound Name	RHEIN		Investigative	[21]
Synonyms	478-43-3; Monorhein; Rheic acid; Rhubarb Yellow; Cassic acid; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; Chrysazin-3-carboxylic acid; 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; NSC 38629; Rheinic acid; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; dipropionyl rhein; 1,8-Dihydroxy-3-carboxyanthraquinone; UNII-YM64C2P6UX; Rhein(Monorhein); 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; CCRIS 5129; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; C15H8O6 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 10168 TTD: D0M2TY DrugBank: DB13174
Compound Name	VER-49009		Investigative	[23]
MOA	Inhibitor
Activity	IC50 = 25 nM
External Link	CID: 4369536 TTD: D0T4MS DrugBank: DB07495
Compound Name	Radicicol		Investigative	[24]
Synonyms	AC1L1JGN; CHEMBL3972342; CTK6B6269 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 150 nM
External Link	CID: 6323491 TTD: D0ZA6G DrugBank: DB03758
Compound Name	Geldanamycin-estradiol hybrid		Investigative	[25]
MOA	Inhibitor
External Link	TTD: D0H6OS
Compound Name	2-Methyl-2,4-Pentanediol		Investigative	[26]
Synonyms	107-41-5; 2-Methylpentane-2,4-diol; Pinakon; 2,4-Dihydroxy-2-methylpentane; 2,4-Pentanediol, 2-methyl-; Diolane; Isol; 4-Methyl-2,4-pentanediol; 1,1,3-Trimethyltrimethylenediol; 2-Methyl pentane-2,4-diol; 2-Methyl-2,4-pentandiol; Caswell No. 574; alpha,alpha,alpha'-Trimethyltrimethylene glycol; 1,3-dimethyl-3-hydroxybutanol; Hexylene glycol [NF]; HSDB 1126; 1,3,3-trimethyl-1,3-propanediol; (+-)-2-Methyl-2,4-pentanediol; NSC 8098; EINECS 203-489-0; EPA Pesticide Chemical Code 068601; BRN Click to Show/Hide
MOA	Inhibitor
External Link	CID: 7870 TTD: D06GOK
2A00: Brain cancer		53 Compound(s) Regulating the Disease	Click to Show/Hide the Full List
Compound Name	Zinostatin stimalamer		Approved	[27]
Synonyms	Smancs (TN) Click to Show/Hide
External Link	CID: 70682998 TTD: D0Z4PE
Compound Name	Motexafin gadolinium		Approved	[28]
Synonyms	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN) Click to Show/Hide
External Link	CID: 158385 TTD: D05BJD DrugBank: DB05428
Compound Name	Lomustine		Approved	[29]
Synonyms	Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea Click to Show/Hide
External Link	CID: 3950 TTD: D04JPJ DrugBank: DB01206
Compound Name	Borocaptate sodium B 10		Approved	[27]
External Link	TTD: D03EOT
Compound Name	DTI-015		Approved	[30]
Synonyms	Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics Click to Show/Hide
External Link	CID: 2578 TTD: D01OXI DrugBank: DB00262
Compound Name	Prinomastat		Approved	[31]
Synonyms	AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide Click to Show/Hide
External Link	CID: 466151 TTD: D00MDP DrugBank: DB05100
Compound Name	INO-1001		Phase 3	[32]
Synonyms	Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one Click to Show/Hide
External Link	CID: 6708742 TTD: D0ZY3E
Compound Name	GliAtak		Phase 3	[33]
Synonyms	GliAtak (TN) Click to Show/Hide
External Link	TTD: D0T3JF
Compound Name	SOT-107		Phase 3	[34]
Synonyms	TransMID Click to Show/Hide
External Link	TTD: D0QL4X
Compound Name	ICT-107		Phase 3	[35]
External Link	TTD: D0M1RD
Compound Name	Cintredekin besudotox		Phase 3	[36]
External Link	TTD: D0G6RB
Compound Name	Rindopepimut		Phase 3	[37]
External Link	TTD: D05FRP
Compound Name	DCVax-Ovarian		Phase 3	[38]
Synonyms	DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics Click to Show/Hide
External Link	TTD: D02XEI
Compound Name	DCVax-Brain		Phase 3	[39]
Synonyms	Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics Click to Show/Hide
External Link	TTD: D02RED
Compound Name	TVI-Brain-1		Phase 2/3	[40]
External Link	TTD: D5A6JN
Compound Name	NLG8189		Phase 2/3	[41]
Synonyms	1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189 Click to Show/Hide
External Link	CID: 405012 TTD: D0B5HS DrugBank: DB12827
Compound Name	Synthetic survivin peptide vaccine		Phase 2	[42]
External Link	TTD: DWZ02M
Compound Name	Fresolimumab		Phase 2	[43]
Synonyms	GC-1008 Click to Show/Hide
External Link	TTD: DB35WK
Compound Name	DNX-2401		Phase 2	[44]
Synonyms	Tasadenoturev Click to Show/Hide
External Link	TTD: D8SV9R
Compound Name	TVI-Brain-1 cancer vaccine		Phase 2	[14]
External Link	TTD: D0ZR6E
Compound Name	PDT with Photofrin		Phase 2	[41]
External Link	TTD: D0XL1T
Compound Name	F18-ML-10		Phase 2	[45]
External Link	TTD: D0K9NJ
Compound Name	PT2385		Phase 2	[46]
Synonyms	ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A Click to Show/Hide
External Link	CID: 91754484 TTD: D0C9PZ
Compound Name	ABT-414		Phase 2	[47]
External Link	TTD: D06XIT
Compound Name	CLR1404-I-124		Phase 1/2	[48]
External Link	TTD: D06EWT
Compound Name	DM-CHOC-PEN		Phase 2	[49]
External Link	CID: 16126905 TTD: D02ZZU DrugBank: DB15075
Compound Name	L-alanosine		Phase 2	[50]
Synonyms	SDX-102 Click to Show/Hide
External Link	CID: 135409347 TTD: D02ELS DrugBank: DB05540
Compound Name	APX005M		Phase 2	[41]
External Link	TTD: D01ZLK
Compound Name	WP-1066		Phase 1/2	[14]
Synonyms	WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312 Click to Show/Hide
External Link	CID: 11210478 TTD: D0IV4C DrugBank: DB12679
Compound Name	Anti-EGFRvIII CAR transduced PBL		Phase 1/2	[51]
External Link	TTD: D08RJY
Compound Name	RG6156		Phase 1	[52]
External Link	TTD: DF8X5N
Compound Name	rhenium-186		Phase 1	[53]
Synonyms	(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM Click to Show/Hide
External Link	CID: 161105 TTD: DB7W8H
Compound Name	IGV-001		Phase 1	[54]
External Link	TTD: D9PM2E
Compound Name	DA-3607		Phase 1	[55]
Synonyms	Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A Click to Show/Hide
External Link	TTD: D0V3ZX
Compound Name	DC/I540/KLH vaccine		Phase 1	[56]
Synonyms	HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber Click to Show/Hide
External Link	TTD: D0RH3S
Compound Name	KX2-361		Phase 1	[57]
Synonyms	KX-02 Click to Show/Hide
External Link	CID: 11545920 TTD: D0RE4L
Compound Name	MR1-1		Phase 1	[58]
Synonyms	MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX Click to Show/Hide
External Link	TTD: D0N3PC
Compound Name	INdoximod + temozolomide		Phase 1	[14]
External Link	TTD: D0B8BY
Compound Name	Anti-CD133-CAR vector-transduced T cells		Phase 1	[59]
External Link	TTD: D09HRH
Compound Name	8H9		Phase 1	[60]
External Link	TTD: D06JAL
Compound Name	CC-8490		Phase 1	[61]
External Link	TTD: D03YGP
Compound Name	Sitimagene ceradenovec		Discontinued in Phase 3	[62]
Synonyms	Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark Click to Show/Hide
External Link	TTD: D0W8RX
Compound Name	Ranagengliotucel-T		Discontinued in Phase 3	[63]
Synonyms	Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx Click to Show/Hide
External Link	TTD: D0N5AY
Compound Name	Oncolysin S		Discontinued in Phase 2	[64]
Synonyms	N901-bR Click to Show/Hide
External Link	TTD: D0H0VW
Compound Name	Labradimil		Discontinued in Phase 2	[65]
Synonyms	Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R,R))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide Click to Show/Hide
External Link	CID: 6918284 TTD: D0G0IZ DrugBank: DB06549
Compound Name	Brain tumor vaccine		Discontinued in Phase 1	[66]
Synonyms	Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC Click to Show/Hide
External Link	TTD: D0JT1P
Compound Name	PCNU		Terminated	[67]
Synonyms	NSC-95466 Click to Show/Hide
External Link	CID: 26328 TTD: D0JI5G
Compound Name	131I-81C6		Terminated	[68]
Synonyms	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6 Click to Show/Hide
External Link	TTD: D07ZKK
Compound Name	NSD-551		Terminated	[69]
Synonyms	BK channel activator (cancer), NeuroSearch/TopoTarget Click to Show/Hide
External Link	TTD: D03QTB
Compound Name	AGT-2000		Investigative	[70]
Synonyms	Gene therapy (intravenous, brain cancer), ArmaGen Click to Show/Hide
External Link	TTD: D0C5WE
Compound Name	NV.XOD.09		Investigative	[71]
External Link	TTD: D02RDC
Compound Name	EDP-19		Investigative	[71]
Synonyms	SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx Click to Show/Hide
External Link	TTD: D02JIF
Compound Name	MIQ-004		Investigative	[71]
Synonyms	M-IQ-004 Click to Show/Hide
External Link	TTD: D01KZV

References

Ref 1	Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a. Clin Transl Med. 2021 Sep;11(9):e424. doi: 10.1002/ctm2.424.
Ref 2	m6A RNA Methylation Controls Proliferation of Human Glioma Cells by Influencing Cell Apoptosis. Cytogenet Genome Res. 2019;159(3):119-125. doi: 10.1159/000499062. Epub 2019 Oct 23.
Ref 3	Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. doi: 10.1042/BJ20030351.
Ref 4	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. doi: 10.2174/187152008785914824.
Ref 5	BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9. doi: 10.1158/1535-7163.MCT-08-0758.
Ref 6	Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68. doi: 10.1038/bcj.2012.13. Epub 2012 Apr 27.
Ref 7	Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8. doi: 10.1517/13543780902953699.
Ref 8	Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23. doi: 10.1345/aph.1M218. Epub 2009 Sep 22.
Ref 9	SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 2009 Jan 22;113(4):846-55. doi: 10.1182/blood-2008-04-151928. Epub 2008 Oct 23.
Ref 10	Clinical pipeline report, company report or official report of Debiopharm (2011).
Ref 11	Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41. doi: 10.1002/pbc.21508.
Ref 12	Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference. Astex. 2008.
Ref 13	Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31. doi: 10.1158/1078-0432.CCR-13-0477. Epub 2013 Jul 19.
Ref 14	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 15	US patent application no. 2013,0023,420, Susceptibility to hsp90-inhibitors.
Ref 16	Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells. Cell Immunol. 2009;259(1):49-55. doi: 10.1016/j.cellimm.2009.05.012. Epub 2009 Jun 6.
Ref 17	Clinical pipeline report, company report or official report of AstraZeneca (2009).
Ref 18	US patent application no. 2014,0079,636, Targeted therapeutics.
Ref 19	WO patent application no. 2013,1734,36, Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status.
Ref 20	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 21	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
Ref 22	Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17. doi: 10.1021/jm9004708.
Ref 23	Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5. doi: 10.1021/jm050355z.
Ref 24	High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem. 2004 Apr 15;327(2):176-83. doi: 10.1016/j.ab.2003.10.038.
Ref 25	Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. doi: 10.1016/s0960-894x(99)00185-7.
Ref 26	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 27	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 28	Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc Interv. 2002 Nov;57(3):387-94.
Ref 29	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7214).
Ref 30	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6800).
Ref 31	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6505).
Ref 32	Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
Ref 33	ClinicalTrials.gov (NCT01436968) Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer. U.S. National Institutes of Health.
Ref 34	ClinicalTrials.gov (NCT00088400) Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors. U.S. National Institutes of Health.
Ref 35	ClinicalTrials.gov (NCT01280552) A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM). U.S. National Institutes of Health.
Ref 36	ClinicalTrials.gov (NCT00076986) The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme. U.S. National Institutes of Health.
Ref 37	ClinicalTrials.gov (NCT01480479) Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma. U.S. National Institutes of Health.
Ref 38	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 39	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017222)
Ref 40	ClinicalTrials.gov (NCT05685004) Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM). U.S.National Institutes of Health.
Ref 41	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 42	ClinicalTrials.gov (NCT05163080) Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE). U.S.National Institutes of Health.
Ref 43	ClinicalTrials.gov (NCT01472731) Safety and Imaging Study of GC1008 in Glioma. U.S. National Institutes of Health.
Ref 44	ClinicalTrials.gov (NCT02798406) Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE). U.S. National Institutes of Health.
Ref 45	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037619)
Ref 46	Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236.
Ref 47	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 48	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034046)
Ref 49	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029242)
Ref 50	ClinicalTrials.gov (NCT00062283) Alanosine in Treating Patients With Cancer. U.S. National Institutes of Health.
Ref 51	ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
Ref 52	Clinical pipeline report, company report or official report of Roche
Ref 53	ClinicalTrials.gov (NCT05460507) A Single Arm Open Label Study to Determine the Safety and Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Recurrence of Glioma in Patients Who Received a Prior Treatment With 186RNL. U.S.National Institutes of Health.
Ref 54	ClinicalTrials.gov (NCT04485949) A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma. U.S.National Institutes of Health.
Ref 55	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026657)
Ref 56	Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leu... Blood. 2006 Oct 15;108(8):2662-8.
Ref 57	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041844)
Ref 58	ClinicalTrials.gov (NCT01009866) Study of Immunotoxin, MR1-1. U.S. National Institutes of Health.
Ref 59	ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ref 60	ClinicalTrials.gov (NCT01502917) Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy. U.S. National Institutes of Health.
Ref 61	ClinicalTrials.gov (NCT00074646) Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas. U.S. National Institutes of Health.
Ref 62	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015264)
Ref 63	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017210)
Ref 64	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006625)
Ref 65	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 672).
Ref 66	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007949)
Ref 67	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000870)
Ref 68	Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998 Oct;4(10):2495-502.
Ref 69	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019960)
Ref 70	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
Ref 71	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.

m6A-centered Crosstalk Information

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map